Literature DB >> 8279027

Interleukin-1 is a critical effector molecule during cytokine dysregulation in graft versus host disease to minor histocompatibility antigens.

S Abhyankar1, D G Gilliland, J L Ferrara.   

Abstract

Cytokines are believed to cause a number of inflammatory diseases. We have investigated the role of 3 inflammatory cytokines, IL-1, IL-2, and TNF alpha, during graft-versus-host disease (GVHD), a paradigm disease of cytokine dysregulation in vivo. Measuring cytokine mRNA transcripts with a quantitative polymerase chain reaction technique, we demonstrate that IL-1 transcript levels are increased several hundred-fold in GVHD target organs, whereas TNF alpha transcripts increase only 4- to 6-fold. Kinetic studies during the first month after transplant unexpectedly show that GVHD never induces IL-2 transcripts in the skin and only induces IL-2 transcripts in the spleen during the first week, whereas levels of IL-1 transcripts continue to increase throughout the entire 4 weeks. Administration of an IL-1 receptor antagonist after the termination of the IL-2 response and after the establishment of GVHD significantly increases long-term survival, confirming the central role of IL-1 as an effector molecule of GVHD and suggesting new therapeutic strategies for this disorder.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8279027     DOI: 10.1097/00007890-199312000-00045

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

1.  Abrogation of donor T-cell IL-21 signaling leads to tissue-specific modulation of immunity and separation of GVHD from GVL.

Authors:  Alan M Hanash; Lucy W Kappel; Nury L Yim; Rebecca A Nejat; Gabrielle L Goldberg; Odette M Smith; Uttam K Rao; Lindsay Dykstra; Il-Kang Na; Amanda M Holland; Jarrod A Dudakov; Chen Liu; George F Murphy; Warren J Leonard; Glenn Heller; Marcel R M van den Brink
Journal:  Blood       Date:  2011-05-19       Impact factor: 22.113

Review 2.  Miniature Swine as a Clinically Relevant Model of Graft-Versus-Host Disease.

Authors:  Raimon Duran-Struuck; Christene A Huang; Katherine Orf; Roderick T Bronson; David H Sachs; Thomas R Spitzer
Journal:  Comp Med       Date:  2015-10       Impact factor: 0.982

3.  Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation.

Authors:  Isao Tawara; Yaping Sun; Eli C Lewis; Tomomi Toubai; Rebecca Evers; Evelyn Nieves; Tania Azam; Charles A Dinarello; Pavan Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

4.  NF-kappaB as a target for the prevention of graft-versus-host disease: comparative efficacy of bortezomib and PS-1145.

Authors:  Sanja Vodanovic-Jankovic; Parameswaran Hari; Paulette Jacobs; Richard Komorowski; William R Drobyski
Journal:  Blood       Date:  2005-09-20       Impact factor: 22.113

5.  Differential roles of IL-1 and TNF-alpha on graft-versus-host disease and graft versus leukemia.

Authors:  G R Hill; T Teshima; A Gerbitz; L Pan; K R Cooke; Y S Brinson; J M Crawford; J L Ferrara
Journal:  J Clin Invest       Date:  1999-08       Impact factor: 14.808

Review 6.  Pathogenesis and management of graft-versus-host disease.

Authors:  Sung W Choi; John E Levine; James L M Ferrara
Journal:  Immunol Allergy Clin North Am       Date:  2010-02       Impact factor: 3.479

7.  Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib.

Authors:  Kai Sun; Lisbeth A Welniak; Angela Panoskaltsis-Mortari; Matthew J O'Shaughnessy; Haiyan Liu; Isabel Barao; William Riordan; Raquel Sitcheran; Christian Wysocki; Jonathan S Serody; Bruce R Blazar; Thomas J Sayers; William J Murphy
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-17       Impact factor: 11.205

8.  Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model.

Authors:  Stephen C Jones; George F Murphy; Thea M Friedman; Robert Korngold
Journal:  J Clin Invest       Date:  2003-12       Impact factor: 14.808

9.  Timing of lymphocyte transfusion and portal clamping for the development of lethal graft-versus-host disease in the rat.

Authors:  E Kobayashi; S Enosawa; A Fujimura; N Kamada; S Suzuki
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 10.  The pathophysiology of acute graft-versus-host disease.

Authors:  James L M Ferrara; Kenneth R Cooke; Takanori Teshima
Journal:  Int J Hematol       Date:  2003-10       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.